MedWatch

Biomarin awaits crucial approvals and flat growth in 2021

2021 could turn out to be an important year for Biomarin, which expects to get a growth hormone against dwarfism approved on the one hand, while battling health authorities in the US and the EU on the other, as the firm attempts to get approvals for its gene therapy against hemophilia.

Photo: Manuel Balce Ceneta/AP/Ritzau Scanpix

In 2020, Biomarin's revenue has increased from USD 1.7bn to USD 1.9bn, which is the highest revenue in the history of the still-growing US company.

The record year came about in spite of the company retreating in Q4 due to postponed orders and competition from generics.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs